Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the italian association of thoracic oncology

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 319-331

  Gridelli, Cesare ^a   Ardizzoni, Andrea ^b   Douillard, Jean Yves ^c   Hanna, Nasser ^d   Manegold, Christian ^e   Perrone, Francesco ^f   Pirker, Robert ^g   Rosell, Rafael ^h   Shepherd, Frances A ⁱ   De Petris, Luigi ^j   Di Maio, Massimo ^f   de Marinis, Filippo ^k  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j KAROLINSKA INSTITUTE   (Sweden)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

Bevacizumab; Cetuximab; Erlotinib; First line chemotherapy; Gefitinib; Non small cell lung cancer; Pemetrexed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; EGFR PROTEIN, HUMAN;

ADVANCED CANCER; ANEMIA; ASIAN; BLEEDING DISORDER; CIGARETTE SMOKING; CLINICAL RESEARCH; CYTOLOGY; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; FEBRILE NEUTROPENIA; HAIR LOSS; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INJECTION SITE REACTION; ITALY; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEX DIFFERENCE; SKIN TOXICITY; THROMBOCYTOPENIA; WORKSHOP; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS DEVELOPMENT; GROUP PROCESS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MEDICAL RESEARCH; MEDICAL SOCIETY; ONCOLOGY; PATHOLOGY; PERSONALIZED MEDICINE;

ANIMALS; BIOMEDICAL RESEARCH; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; GROUP PROCESSES; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PLATINUM COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOCIETIES, MEDICAL;

EID: 77952583078     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.11.018     Document Type: Review

References (56)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002, 346:92-98.
3. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
4. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
5. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
6. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007, 2:939-946.
7. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14:497-510.
8. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV. Non-Small-Cell Lung Cancer. J Clin Oncol. 2009 Nov 23. [Epub ahead of print].
9. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology. Non-small-cell lung cancer. Version 2.2009. [Accessed 20 August 2009]. http://www.nccn.org/.
10. Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):277S-289S.
11. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
12. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234. [Erratum in J Clin Oncol 2009;27:2415].
13. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
14. Sandler A.B., Schiller J.H., Gray R., Dimery I., Brahmer J., Samant M., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009, 27:1405-1412.
15. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. BO17704 (AVAiL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous, non-small-cell-lung cancer. Abstract book of the 33rd European society of medical oncology congress. Stockholm, Sweden. 12-16 September 2008. Ann Oncol 2008;19(Suppl 8):viii1 [abstr LBA1].
16. Crinò L, Mezger J, Griesinger F, Zhou C, Reck M. MO19390 (SAiL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:15s [abstr 8043].
17. Thatcher N, Tsai CM, Laskin J, Crinò L, Pavlakis N, Garrido P, et al. MO19390 (SAiL): hypertension in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy. WCLC 2009 - 13th world conference on lung cancer. J Thorac Oncol 2009; 4(9):S5-968 [abstr C2.4].
18. Akerley WL, Langer CJ, Oh Y, Strickland DK, Joo Royer S, Xia Q, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008;26 [abstr 8043].
19. Ramalingam S.S., Dahlberg S.E., Langer C.J., Gray R., Belani C.P., Brahmer J.R., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
20. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
21. O'Byrne KJ, Bondarenko I, Barrios C, Eschbach C, Martens U, Hotko Y, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009;27:15s [abstr 8007].
22. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann R, et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): BMS 099. Presented at the 12th world congress on lung cancer. 2-6 September 2007. Seoul, Korea. J Thorac Oncol 2007;2(Suppl 4):S340-1 [abstr B3-03].
23. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25:5777-84 [erratum in J Clin Oncol 2008;26:3295].
24. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
25. Thatcher N, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Pujol JL, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer: a meta-analysis of randomized phase II/III trials. WCLC 2009 - 13th world conference on lung cancer. J Thorac Oncol 2009;4(9):S5-968 [abstr A3.7].
26. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
27. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
28. Peterson P, Park K, Fossella F, Gatzemeier F, Ulrich J, Scagliotti G. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). The European cancer conference 2007 (ECCO 14). Eur J Cancer Suppl 2007;5(4):363 [abstr P#6521].
29. Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008;26 [abstr 8011].
30. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 2009;27:18s [abstr CRA8000].
31. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24.
32. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22:777-784.
33. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22:785-794.
34. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
35. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
36. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
37. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
38. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase III trial. Lancet 2008, 372:1809-1818.
39. Shepherd FA, Douillard JY, Fukuoka M, Saijo N, Kim S, Cufer T, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials. J Clin Oncol 2009;27:15s [abstr 8011].
40. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44 [erratum in N Engl J Med 2006;355:174].
41. Douillard J, Hirsh V, Mok TS, Socinski MA, Watkins C, Lowe E, et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008;26 [abstr 8001].
42. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
43. Goldberg P. Iressa Authorization in Europe Clarifies Differences Between U.S., E.U. Standards. Cancer Lett 2009;35:1-4.
44. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
45. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009;27:15s [abstr 8016].
46. Tsurutani J, Mitsudomi T, Mori S, et al. A phase III, first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: preliminary results of WJTOG 3405. Presented at ECCO/ESMO. Berlin, 2009. [abstr 9.002].
47. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):68-70. ESMO Guidelines Working Group.
48. Socinski M.A. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?. J Clin Oncol 2009, 27:3268-3270.
49. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
50. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27:15s [abstr 8001].
51. Miller VA, O'Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:18s [abstr LBA8002].
52. Brugger W, Kim JH, Hansen O, Sullivan R, White S, Lee JS, et al. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC. WCLC 2009 - 13th world conference on lung cancer. J Thorac Oncol 2009;4(9):S5-968 [abstr B9.1].
53. Cappuzzo F, Coudert BP, Wierzbicki R, Wu YL, Gonzalez EE, Davidson N, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III Saturn study. WCLC 2009 - 13th world conference on lung cancer. J Thorac Oncol 2009;4(9):S5-968 [abstr A2.1].
54. Scagliotti GV, Ceppi P, Novello S, Capotti M. Chemotherapy treatment decisions in advanced non-small cell lung cancer based on histology. American society of clinical oncology educational book; 2009. p. 431-5.
55. Grilley-Olson JE, Hayes DN, Qaqish BF, Moore DT, Socinski MA, Yin X, et al. Validation of inter-observer agreement in lung cancer assessment; diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: a large prospective study. J Clin Oncol 2009;27:15s [abstr 8008].
56. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the 440 billion question. J Natl Cancer Inst 2009;101:1044-8.